<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951546</url>
  </required_header>
  <id_info>
    <org_study_id>RIF.CE:4119</org_study_id>
    <nct_id>NCT02951546</nct_id>
  </id_info>
  <brief_title>Study on Metabolic Flexibility and Gut Microbiota Composition in Obese Subjects With NAFLD, Taking Into Account PNPLA3 and TM6SF2 Polymorphisms. Effects of Nutritional Intervention Combined to Exercise</brief_title>
  <official_title>Body Composition, Adiposity Phenotype, Metabolic Flexibility, and Gut Microbiota in PNPLA3 and TM6SF2 Gene Variant Carriers and Non-carriers With Nonalcoholic Fatty Liver Disease and Obesity. Effects of a Nutritional Intervention Combined to Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli studi di Roma Foro Italico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) is frequently associated with obesity. NAFLD genetic
      susceptibility involves Patatin Like Phospholipase Domain Containing 3 (PNPLA3) rs738409 and
      Transmembrane 6 Superfamily Member 2 (TM6SF2) rs58542926 polymorphisms.

      To date, biochemical mechanisms that affect the &quot;metabolic flexibility&quot; in obese NAFLD
      subjects, in presence or absence of genetic susceptibility, need to be better clarified.

      Different studies demonstrated that a dietary intervention, accompanied by a physical
      personalized training, significantly reduce either the hepatic fat content either insulin
      resistance in overweight and obese subjects, independently of weight loss.

      On these bases, the aim of the study is to evaluate &quot;metabolic flexibility&quot; in obese NAFLD
      subjects taking in account their genetics (presence or absence of PNPLA3 and TM6SF2
      polymorphisms) and the histopathological diagnosis of either simple steatosis or nonalcoholic
      steatohepatitis (NASH). In addition, the composition of gut microbiota will be evaluated.

      Finally, in this study, two distinct healthy dietary profiles accompanied by a personalized
      physical training, will be tested in order to comprehend whether and how &quot;healthy diets&quot;
      could be effective not only in the prevention, but also in the clinical treatment of NAFLD
      and other related conditions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metabolic flexibility variation in lipid profile;</measure>
    <time_frame>baseline and after 18 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolic flexibility variation in glucidic profile</measure>
    <time_frame>baseline and after 18 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Mediterranean diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypocaloric Mediterranean diet for a 4-month period;
Aerobic exercise training for a 4-month period;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low fat diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;
Aerobic exercise training for a 4- month period;</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mediterranean diet</intervention_name>
    <description>In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol &lt;300 mg/day, dietary fiber 25 g/day.</description>
    <arm_group_label>Mediterranean diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low fat diet</intervention_name>
    <description>In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.</description>
    <arm_group_label>Low fat diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic exercise</intervention_name>
    <description>A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the &quot;FITT&quot; principles (frequency, intensity, time and type).</description>
    <arm_group_label>Mediterranean diet</arm_group_label>
    <arm_group_label>Low fat diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) &gt; 30 Kg/m2 and &lt; 40 Kg/m2;

          -  Caucasian Italian subjects

          -  hepatic steatosis according with ultrasonographic Hamaguchi's criteria and/or
             hypertransaminasemia (ALT &gt;30 IU/L in men and &gt;20 IU/L in women)

        Exclusion Criteria:

          -  any malignant disease during the last 5 years;

          -  any inflammatory or autoimmune disease;

          -  corticosteroids for systemic use;

          -  renal failure (GFR&lt;90 ml/min);

          -  heart failure (NYHA classes II-IV);

          -  history of viral or autoimmune liver disease;

          -  any cause cirrhosis;

          -  excessive alcohol intake (&gt;140g/week for men and 70g/week for women);

          -  participation in a reducing-weight program in the last 3 months;

          -  level of physical activity higher than 3 METs;

          -  therapy with antibiotics during the last 3 months;

          -  bile salts, cholestyramine during the last 6 months before enrollment;

          -  previous cholecystectomy;

          -  gallbladder disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Ginanni Corradini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Medicine, Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Ginanni Corradini, MD, PhD</last_name>
    <phone>+39 0649972086</phone>
    <email>stefano.corradini@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorenzo Maria Donini, MD, PhD</last_name>
    <phone>+39 0649910996</phone>
    <email>lorenzomaria.donini@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stefano Ginanni Corradini</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Ginanni Corradini, MD, PhD</last_name>
      <phone>+39 0649972086</phone>
      <email>stefano.corradini@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Medicine, Sapienza University of Rome, Umberto I Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Ginanni Corradini, MD, PhD</last_name>
      <phone>+39 0649972086</phone>
      <email>stefano.corradini@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>Fredrik Bäckhed, MD, PhD</last_name>
      <phone>+46 (0)31-342 7833</phone>
      <email>fredrik.backhed@wlab.gu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Stefano Ginanni Corradini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Maria Donini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucio Gnessi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Catalano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriano De Santis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maurizio Cardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Adamo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Di Cristofano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Migliaccio, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fredrik Backhed, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fiorella Piemonte, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora Poggiogalle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edoardo Poli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flaminia Ferri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulia Tozzi, BSD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica D'Amico, TSD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Pintore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Molinaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Mischitelli, BSD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benedetta Meloni, Collaborator</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michela Rofei, Collaborator</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bianca Sollazzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa Marcellinaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carla Lubrano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Ciccantelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecilia Mancini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michele Di Martino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessio Farcomeni, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Spagnoli, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Barbaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>STEFANO GINANNI CORRADINI</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

